News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis
SAN CARLOS, Calif. , July 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to its New Drug Application (NDA) for avacopan for the treatment of Anti-neutrophil
View HTML
Toggle Summary ChemoCentryx to Participate in the Raymond James 2021 Human Health Innovations Conference
SAN CARLOS, Calif. , June 16, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Raymond James 2021 Human Health Innovations Conference on Wednesday, June 23
View HTML
Toggle Summary ChemoCentryx Announces Abstract on Avacopan in ANCA-Associated Vasculitis Selected as One of the Ten Best Abstracts at the ERA-EDTA Congress
-- Abstract on ‘The Effect of Avacopan, a Complement C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis with Renal Disease’ honored on “Ten Best” list by the Paper Selection Committee of ERA-EDTA -- -- Abstract on the Phase II ACCOLADE Study of Avacopan for the
View HTML
Toggle Summary ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis
SAN CARLOS, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory Committee (“Committee”) on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody
View HTML
Toggle Summary ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights
-- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the United States , Europe and Japan ; PDUFA goal date of July 7, 2021 , with Advisory Committee scheduled for May 6 -- -- Novel orally administered checkpoint inhibitor CCX559 featured at American
View HTML
Toggle Summary ChemoCentryx to Hold First Quarter 2021 Financial Results Conference Call on Thursday, April 29, 2021
MOUNTAIN VIEW, Calif. , April 22, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's first quarter 2021 financial results will be released after market close on Thursday, April 29, 2021 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting
-- CCX559 enhanced primary human T cell activity in vitro and demonstrated anti-tumor efficacy in two murine tumor models -- -- Company plans to advance CCX559 into clinical development in the first half of 2021 -- MOUNTAIN VIEW, Calif. , April 09, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
View HTML
Toggle Summary ChemoCentryx to Host Virtual R&D Day on April 14, 2021
MOUNTAIN VIEW, Calif. , April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. ET . The event will feature a panel of key opinion leaders, a testimonial from a patient living
View HTML
Toggle Summary ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors
MOUNTAIN VIEW, Calif. , March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya , the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021
View HTML
Toggle Summary ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- -- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the U.S. (PDUFA goal date of July 7, 2021 ), the E.U.
View HTML